195 related articles for article (PubMed ID: 31522424)
1. Immunophenotyping of Acute Myeloid Leukemia.
Galera PK; Jiang C; Braylan R
Methods Mol Biol; 2019; 2032():281-296. PubMed ID: 31522424
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotyping by Multiparameter Flow Cytometry.
Chen W; Luu HS
Methods Mol Biol; 2017; 1633():51-73. PubMed ID: 28735480
[TBL] [Abstract][Full Text] [Related]
3. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
Al-Mawali A; Gillis D; Lewis I
Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood flow cytometry for the diagnosis of pediatric acute leukemia: Highly reliable with rare exceptions.
Cheng J; Klairmont MM; Choi JK
Pediatr Blood Cancer; 2019 Jan; 66(1):e27453. PubMed ID: 30255571
[TBL] [Abstract][Full Text] [Related]
5. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
Kern W; Danhauser-Riedl S; Ratei R; Schnittger S; Schoch C; Kolb HJ; Ludwig WD; Hiddemann W; Haferlach T
Haematologica; 2003 Jun; 88(6):646-53. PubMed ID: 12801840
[TBL] [Abstract][Full Text] [Related]
6. Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia.
Rossi G; Giambra V; Minervini MM; De Waure C; Mancinelli S; Ciavarella M; Sinisi NP; Scalzulli PR; Carella AM; Cascavilla N
Cytometry B Clin Cytom; 2020 May; 98(3):216-225. PubMed ID: 31697027
[TBL] [Abstract][Full Text] [Related]
7. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
Al-Mawali A; Gillis D; Hissaria P; Lewis I
Am J Clin Pathol; 2008 Jun; 129(6):934-45. PubMed ID: 18480011
[TBL] [Abstract][Full Text] [Related]
8. Clinically useful flow cytometry approach to identify immunophenotype in acute leukemia.
Ouyang G; Xu Z; Jiang D; Zhu H; Wang Y; Wu W; Sun Y; Sheng L; Xu K; Lou Y; Mu Q; Zhang Y; Wu N; Cheng J; Duan S
J Int Med Res; 2019 Apr; 47(4):1483-1492. PubMed ID: 30614357
[TBL] [Abstract][Full Text] [Related]
9. [Detection of Minimal Residual Disease in Acute Myeloid Leukemia by Multi-color Flow Cytometry].
He C; Zhang QT; Tang P; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):341-345. PubMed ID: 35395960
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
[TBL] [Abstract][Full Text] [Related]
11. [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
Kern W; Haferlach T
Med Klin (Munich); 2005 Jan; 100(1):54-9. PubMed ID: 15654545
[TBL] [Abstract][Full Text] [Related]
12. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
14. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
[TBL] [Abstract][Full Text] [Related]
15. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
Li X; Du W; Liu W; Li X; Li H; Huang SA
APMIS; 2010 May; 118(5):353-9. PubMed ID: 20477810
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.
Ouyang J; Goswami M; Peng J; Zuo Z; Daver N; Borthakur G; Tang G; Medeiros LJ; Jorgensen JL; Ravandi F; Wang SA
Am J Clin Pathol; 2016 Jun; 145(6):769-77. PubMed ID: 27298396
[TBL] [Abstract][Full Text] [Related]
18. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
[TBL] [Abstract][Full Text] [Related]
20. Monitoring minimal residual disease in AML.
Stewart CC
Cytotherapy; 1999; 1(4):341. PubMed ID: 20426562
[No Abstract] [Full Text] [Related]
[Next] [New Search]